Parenteral versus oral methotrexate for the treatment of rheumatoid arthritis: a review of the clinical evidence
Canadian Agency for Drugs and Technologies in Health
Record ID 32011000942
English
Authors' recommendations:
One randomized controlled trial suggests that the subcutaneous form of methotrexate may be more effective than the oral form for the treatment of early rheumatoid arthritis; however, guidelines recommend a preference for the oral route with a switch to parenteral administration for patients who experience inadequate response or intolerance.
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/htis/may-2011/RC0265_Methotrexate_for_Rheumatoid_Arthritis_final.pdf
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Infusions, Parenteral
- Arthritis, Rheumatoid
- Methotrexate
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.